8-K: Owlet Secures $9 Million in Private Placement Following FDA Clearances and Strong Preliminary Q4 Results

Owlet, Inc. has announced a $9 million private placement of Series B convertible preferred stock and warrants, following recent FDA clearances and strong preliminary fourth quarter results.

Summary

• Owlet, Inc. has entered into a definitive agreement for a private placement, raising approximately $9 million before expenses.
• The financing involves the issuance of Series B convertible preferred stock and warrants to purchase Class A common stock.
• The conversion ratio for the preferred stock and the exercise price for the warrants represent a 25% premium to the closing market price on February 23, 2024.
• The private placement is expected to close on or about February 28, 2024, subject to customary closing conditions.
• The company plans to use the net proceeds for general corporate purposes and to fund strategic initiatives.
• The Series B preferred stock will be convertible into approximately 1.2 million shares of common stock.
• Each purchaser will also receive warrants to purchase 150% of the number of shares of common stock into which their Series B preferred stock is convertible.
• The warrants have an exercise price of $7.7125 per share and a five-year term.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful private placement, strong preliminary Q4 results, and recent FDA clearances. The 25% premium on the conversion and exercise prices also indicates strong investor confidence. However, the potential for dilution and the inherent risks of the business temper the overall sentiment.

Positives

• The private placement provides Owlet with additional capital to support its strategic initiatives.
• The 25% premium on the conversion and exercise prices indicates strong investor confidence.
• The company's recent FDA clearances and strong preliminary fourth quarter results suggest positive momentum.
• The participation of existing investors demonstrates their continued support for the company.
• The company has a strong cash position of over $16 million.

Negatives

• The private placement will result in dilution of existing shareholders due to the issuance of new shares.
• The warrants could further dilute shareholders if exercised.

Risks

• The private placement is subject to customary closing conditions, which may not be met.
• The company's future performance is subject to various risks and uncertainties, as detailed in their SEC filings.
• The company's ability to achieve profitability is not guaranteed.
• The company operates in an evolving environment, and new risks may emerge.

Future Outlook

The company plans to use the proceeds to support its strategic initiatives and commercialize its new medical devices globally. The company is also focused on achieving a profitable business.

Management Comments

• Kurt Workman, Co-founder and CEO, stated that the capital is important in supporting the company's momentum after recent FDA clearances.
• Workman also expressed gratitude for the investors who share the company's vision and passion for improving pediatric health.
• Workman highlighted the team's commitment to operating towards achieving a profitable business.

Industry Context

This private placement comes at a time when Owlet is experiencing positive momentum with recent FDA clearances for its new medical devices. The financing will support the company's growth and expansion in the smart infant monitoring market.

Comparison to Industry Standards

• The 25% premium on the conversion and exercise prices suggests a strong valuation compared to industry averages for similar private placements.
• The participation of existing investors is a positive sign, indicating confidence in the company's future prospects.
• The company's focus on achieving profitability aligns with industry trends towards sustainable growth.

Related Party Transactions

• Investors who are purchasing Preferred Shares and Warrants in the Private Placement include (i) an entity affiliated with Eclipse Ventures LLC (Eclipse), (ii) entities affiliated with Trilogy Equity Partners, LLC (Trilogy), and (iii) John Kim, a member of the Companys board of directors (the Board).
• Lior Susan, the chairman of the Board, and Marc Stoll, a member of the Board, are affiliated with Eclipse and Amy McCullough, a member of the Board, is affiliated with Trilogy.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees may benefit from the company's increased financial stability and growth prospects.
• Customers may see improved products and services as the company invests in its strategic initiatives.
• Creditors may view the company as a more stable borrower due to the increased capital.

Next Steps

• The private placement is expected to close on or about February 28, 2024.
• The company will file a registration statement with the SEC to register the resale of the shares of common stock underlying the Series B preferred stock and warrants.

Key Dates

Keywords

private placement, Series B preferred stock, warrants, convertible, FDA clearance, financing, equity, strategic initiatives, dilution, institutional investors